Share on StockTwits
 

Equities researchers at Needham & Company initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $14.00 price target on the stock. Needham & Company’s price objective suggests a potential upside of 43.88% from the company’s current price.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 9.73 on Tuesday. BioCryst Pharmaceuticals has a one year low of $1.12 and a one year high of $12.35. The stock’s 50-day moving average is $9.83 and its 200-day moving average is $7.12. The company’s market cap is $575.0 million. BioCryst Pharmaceuticals also saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 5,356,831 shares, a decrease of 31.4% from the January 15th total of 7,809,393 shares. Based on an average trading volume of 1,550,929 shares, the short-interest ratio is presently 3.5 days. Approximately 10.6% of the shares of the stock are sold short.

BCRX has been the subject of a number of other recent research reports. Analysts at Bank of America downgraded shares of BioCryst Pharmaceuticals to an “underperform” rating in a research note on Tuesday, January 28th. Finally, analysts at Wells Fargo & Co. downgraded shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $13.67.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.